Despite the continuing development of immunomodulatory agents and supportive care, the
prognosis associated with lupus nephritis (LN) has not improved substantially in the past …

Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant
disease, characterized by multiple organ damage, that in its most severe forms can be life …

Objectives To update the EULAR recommendations for the management of systemic lupus
erythematosus (SLE) based on emerging new evidence. Methods An international Task …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of
clinical manifestations and a relapsing-remitting course. New data regarding pathogenic …

Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with highly
heterogeneous clinical symptoms and severity. There is complex pathogenesis of SLE, one …

Systemic lupus erythematosus (SLE) is a disease of immune complex deposition; therefore,
complement plays a vital role in the pathogenesis of SLE. In general, complement levels in …

Treatment of systemic lupus erythematosus (SLE) currently employs agents with relatively
unselective immunosuppressive properties. However, two target-specific biological drugs …

Background Systemic lupus erythematosus (SLE) is heterogeneous in organ involvement
and disease severity, presenting a broad clinical phenotype. Systemic type I interferon (IFN) …

Despite an unprecedented rise in the number of biological therapies developed for systemic
lupus erythematosus (SLE) during the last decades, most randomised clinical trials (RCTs) …